{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:15:58Z","timestamp":1792430158410,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872081"],"award-info":[{"award-number":["81872081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>TP53 is a classic tumor suppressor, but its role in kidney cancer remains unclear. In our study, we tried to explain the role of p53 in kidney cancer through the p53-related enhancer RNA pathway. Functional experiments were used to explore whether P53-bound enhancer regions 2 (p53BER2) has a role in the cell cycle and senescence response of TP53-wild type (WT) renal cancer cells in vitro or vivo. RNA-sequencing was used to identify the potential target of p53BER2. The results showed that the expression level of P53BER2 was downregulated in renal cancer tissues and cell lines, further dual-luciferase experiments and APR-256-reactivated experiments showed p53BER2 expresses in a p53-dependent way. Moreover, knockdown p53BER2 could reverse nutlin-3-induced cytotoxic effect in TP53-WT cell lines. Further exploration showed the downregulation of p53BER2 could reverse nutlin-3-induced G1-arrest and senescence in TP53-WT cell lines. What is more, the knockdown of p53BER2 showed resistance to nutlin-3 treatment in vivo. Additionally, we found BRCA2 could be regulated by p53BER2 in vitro and vivo; further experiment showed p53BER2 could induce cell-cycle arrest and DNA repair by mediating BRCA2. In summary, the p53-associated enhancer RNA-p53BER2 mediates the cell cycle and senescence of p53 in TP53-WT renal cancer cells.<\/jats:p>","DOI":"10.1038\/s41419-020-03229-8","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T19:07:49Z","timestamp":1610046469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway"],"prefix":"10.1038","volume":"12","author":[{"given":"Haibiao","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-5667","authenticated-orcid":false,"given":"Jingcheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-677X","authenticated-orcid":false,"given":"Kan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"3229_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"3229_CR2","first-page":"341","volume":"18","author":"JL Godwin","year":"2014","unstructured":"Godwin, J. L., Zibelman, M., Plimack, E. R. & Geynisman, D. M. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov. Med. 18, 341\u2013350 (2014).","journal-title":"Discov. Med."},{"key":"3229_CR3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/1097-0142(19940801)74:3<916::AID-CNCR2820740319>3.0.CO;2-Z","volume":"74","author":"JA Kish","year":"1994","unstructured":"Kish, J. A. et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74, 916\u2013919 (1994).","journal-title":"Cancer"},{"key":"3229_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","volume":"74","author":"SW Lowe","year":"1993","unstructured":"Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957\u2013967 (1993).","journal-title":"Cell"},{"key":"3229_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nrc864","volume":"2","author":"KH Vousden","year":"2002","unstructured":"Vousden, K. H. & Lu, X. Live or let die: the cell\u2019s response to p53. Nat. Rev. Cancer 2, 594\u2013604 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"3229_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307\u2013310 (2000).","journal-title":"Nature"},{"key":"3229_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/path.1838","volume":"207","author":"R Nenutil","year":"2005","unstructured":"Nenutil, R. et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J. Pathol. 207, 251\u2013259 (2005).","journal-title":"J. Pathol."},{"key":"3229_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/sj.bjc.6602358","volume":"92","author":"AJ Munro","year":"2005","unstructured":"Munro, A. J., Lain, S. & Lane, D. P. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br. J. Cancer 92, 434\u2013444 (2005).","journal-title":"Br. J. Cancer"},{"key":"3229_CR9","doi-asserted-by":"publisher","first-page":"6498","DOI":"10.1158\/0008-5472.CAN-05-0017","volume":"65","author":"HE Warburton","year":"2005","unstructured":"Warburton, H. E. et al. p53 regulation and function in renal cell carcinoma. Cancer Res. 65, 6498\u20136503 (2005).","journal-title":"Cancer Res."},{"key":"3229_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/BF00192110","volume":"426","author":"G Chemeris","year":"1995","unstructured":"Chemeris, G., Loktinov, A., Rempel, A., Schwarz, M. & Bannasch, P. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Arch. Int. J. Pathol. 426, 563\u2013569 (1995).","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"3229_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/cncr.24841","volume":"116","author":"AP Noon","year":"2010","unstructured":"Noon, A. P. et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer 116, 780\u2013790 (2010).","journal-title":"Cancer"},{"key":"3229_CR12","first-page":"766","volume":"7","author":"Y Imai","year":"1994","unstructured":"Imai, Y., Strohmeyer, T. G., Fleischhacker, M., Slamon, D. J. & Koeffler, H. P. p53 mutations and MDM-2 amplification in renal cell cancers. Mod. Pathol. 7, 766\u2013770 (1994).","journal-title":"Mod. Pathol."},{"key":"3229_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/BF00194605","volume":"424","author":"Y Kikuchi","year":"1994","unstructured":"Kikuchi, Y., Kishi, T., Suzuki, M., Furusato, M. & Aizawa, S. Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas. Virchows Arch. Int. J. Pathol. 424, 229\u2013233 (1994).","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"3229_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2014.07.024","volume":"353","author":"R Polanski","year":"2014","unstructured":"Polanski, R. et al. Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism. Cancer Lett. 353, 211\u2013219 (2014).","journal-title":"Cancer Lett."},{"key":"3229_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.4161\/cbt.10.12.13612","volume":"10","author":"CC Tsao","year":"2010","unstructured":"Tsao, C. C. & Corn, P. G. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines. Cancer Biol. Ther. 10, 1315\u20131325 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"3229_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nature10006","volume":"474","author":"D Wang","year":"2011","unstructured":"Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390\u2013394 (2011).","journal-title":"Nature"},{"key":"3229_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000384","volume":"8","author":"F De Santa","year":"2010","unstructured":"De Santa, F. et al. A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol. 8, e1000384 (2010).","journal-title":"PLoS Biol."},{"key":"3229_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature09033","volume":"465","author":"TK Kim","year":"2010","unstructured":"Kim, T. K. et al. Widespread transcription at neuronal activity-regulated enhancers. Nature 465, 182\u2013187 (2010).","journal-title":"Nature"},{"key":"3229_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nature12210","volume":"498","author":"W Li","year":"2013","unstructured":"Li, W. et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 498, 516\u2013520 (2013).","journal-title":"Nature"},{"key":"3229_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.tig.2015.11.004","volume":"32","author":"Y Murakawa","year":"2016","unstructured":"Murakawa, Y. et al. Enhanced identification of transcriptional enhancers provides mechanistic insights into diseases. Trends Genet. 32, 76\u201388 (2016).","journal-title":"Trends Genet."},{"key":"3229_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2010.06.040","volume":"142","author":"M Huarte","year":"2010","unstructured":"Huarte, M. et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142, 409\u2013419 (2010).","journal-title":"Cell"},{"key":"3229_CR22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.molcel.2012.11.021","volume":"49","author":"CA Melo","year":"2013","unstructured":"Melo, C. A. et al. eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol. Cell 49, 524\u2013535 (2013).","journal-title":"Mol. Cell"},{"key":"3229_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.cell.2011.03.035","volume":"145","author":"CA Brady","year":"2011","unstructured":"Brady, C. A. et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571\u2013583 (2011).","journal-title":"Cell"},{"key":"3229_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.canlet.2018.02.038","volume":"422","author":"H Xie","year":"2018","unstructured":"Xie, H. et al. Synthetic artificial \u201clong non-coding RNAs\u201d targeting oncogenic microRNAs and transcriptional factors inhibit malignant phenotypes of bladder cancer cells. Cancer Lett. 422, 94\u2013106 (2018).","journal-title":"Cancer Lett."},{"key":"3229_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.7150\/ijbs.29737","volume":"15","author":"B Hong","year":"2019","unstructured":"Hong, B. et al. TRIB3 promotes the proliferation and invasion of renal cell carcinoma cells via activating MAPK signaling pathway. Int J. Biol. Sci. 15, 587\u2013597 (2019).","journal-title":"Int J. Biol. Sci."},{"key":"3229_CR26","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1101\/gad.10.19.2438","volume":"10","author":"X Chen","year":"1996","unstructured":"Chen, X., Ko, L. J., Jayaraman, L. & Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438\u20132451 (1996).","journal-title":"Genes Dev."},{"key":"3229_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/abbs\/gmq009","volume":"42","author":"L Sun","year":"2010","unstructured":"Sun, L. et al. The location of endogenous wild-type p53 protein in 293T and HEK293 cells expressing low-risk HPV-6E6 fusion protein with GFP. Acta Biochim. Biophys. Sin. 42, 230\u2013235 (2010).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"3229_CR28","doi-asserted-by":"publisher","first-page":"C1110","DOI":"10.1152\/ajpcell.00217.2010","volume":"299","author":"H Shimizu","year":"2010","unstructured":"Shimizu, H. et al. Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am. J. Physiol. Cell Physiol. 299, C1110\u2013C1117 (2010).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"3229_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm0302-282","volume":"8","author":"VJ Bykov","year":"2002","unstructured":"Bykov, V. J. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282\u2013288 (2002).","journal-title":"Nat. Med."},{"key":"3229_CR30","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/S0959-8049(03)00454-4","volume":"39","author":"VJ Bykov","year":"2003","unstructured":"Bykov, V. J., Selivanova, G. & Wiman, K. G. Small molecules that reactivate mutant p53. Eur. J. cancer 39, 1828\u20131834 (2003).","journal-title":"Eur. J. cancer"},{"key":"3229_CR31","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-10-3168","volume":"17","author":"R Zandi","year":"2011","unstructured":"Zandi, R. et al. PRIMA-1Met\/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin. Cancer Res. 17, 2830\u20132841 (2011).","journal-title":"Clin. Cancer Res."},{"key":"3229_CR32","doi-asserted-by":"publisher","unstructured":"Kong, N. et al. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci. Transl. Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aaw1565 (2019).","DOI":"10.1126\/scitranslmed.aaw1565"},{"key":"3229_CR33","doi-asserted-by":"publisher","first-page":"a026104","DOI":"10.1101\/cshperspect.a026104","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen, J. The Cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb. Perspect. Med. 6, a026104 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"3229_CR34","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1038\/onc.2012.640","volume":"32","author":"A Rufini","year":"2013","unstructured":"Rufini, A., Tucci, P., Celardo, I. & Melino, G. Senescence and aging: the critical roles of p53. Oncogene 32, 5129\u20135143 (2013).","journal-title":"Oncogene"},{"key":"3229_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2011","unstructured":"Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68\u201378 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"3229_CR36","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ymthe.2017.12.015","volume":"26","author":"EJ Lee","year":"2018","unstructured":"Lee, E. J. et al. Hepatocyte growth factor improves the therapeutic efficacy of human bone marrow mesenchymal stem cells via RAD51. Mol. Ther. 26, 845\u2013859 (2018).","journal-title":"Mol. Ther."},{"key":"3229_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13608-1","volume":"10","author":"W Cai","year":"2019","unstructured":"Cai, W. et al. PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nat. Commun. 10, 5800 (2019).","journal-title":"Nat. Commun."},{"key":"3229_CR38","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/jnci\/86.19.1470","volume":"86","author":"DL Uhlman","year":"1994","unstructured":"Uhlman, D. L. et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J. Natl Cancer Inst. 86, 1470\u20131475 (1994).","journal-title":"J. Natl Cancer Inst."},{"key":"3229_CR39","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature05529","volume":"445","author":"W Xue","year":"2007","unstructured":"Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656\u2013660 (2007).","journal-title":"Nature"},{"key":"3229_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature07672","volume":"458","author":"M Guttman","year":"2009","unstructured":"Guttman, M. et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458, 223\u2013227 (2009).","journal-title":"Nature"},{"key":"3229_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7520","volume":"6","author":"N Leveille","year":"2015","unstructured":"Leveille, N. et al. Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. Nat. Commun. 6, 6520 (2015).","journal-title":"Nat. Commun."},{"key":"3229_CR42","doi-asserted-by":"publisher","first-page":"909","DOI":"10.15252\/embj.201693860","volume":"35","author":"J Michl","year":"2016","unstructured":"Michl, J., Zimmer, J. & Tarsounas, M. Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. EMBO J. 35, 909\u2013923 (2016).","journal-title":"EMBO J."},{"key":"3229_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.molcel.2015.12.004","volume":"61","author":"J Zimmer","year":"2016","unstructured":"Zimmer, J. et al. Targeting BRCA1 and BRCA2 deficiencies with G-Quadruplex-interacting compounds. Mol. Cell 61, 449\u2013460 (2016).","journal-title":"Mol. Cell"},{"key":"3229_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15983","volume":"8","author":"X Lai","year":"2017","unstructured":"Lai, X. et al. MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells. Nat. Commun. 8, 15983 (2017).","journal-title":"Nat. Commun."},{"key":"3229_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ng1297-423","volume":"17","author":"F Connor","year":"1997","unstructured":"Connor, F. et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat. Genet. 17, 423\u2013430 (1997).","journal-title":"Nat. Genet."},{"key":"3229_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11048-5","volume":"10","author":"T Reislander","year":"2019","unstructured":"Reislander, T. et al. BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat. Commun. 10, 3143 (2019).","journal-title":"Nat. Commun."},{"key":"3229_CR47","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King, M. C., Marks, J. H. & Mandell, J. B. & New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643\u2013646 (2003).","journal-title":"Science"},{"key":"3229_CR48","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","volume":"91","author":"J Peto","year":"1999","unstructured":"Peto, J. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl Cancer Inst. 91, 943\u2013949 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"3229_CR49","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ng747","volume":"29","author":"J Jonkers","year":"2001","unstructured":"Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418\u2013425 (2001).","journal-title":"Nat. Genet."},{"key":"3229_CR50","doi-asserted-by":"publisher","first-page":"15652","DOI":"10.1074\/jbc.M211297200","volume":"278","author":"K Wu","year":"2003","unstructured":"Wu, K., Jiang, S. W. & Couch, F. J. p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage. J. Biol. Chem. 278, 15652\u201315660 (2003).","journal-title":"J. Biol. Chem."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03229-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03229-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:39:41Z","timestamp":1669919981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03229-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["3229"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-03229-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"30 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The project was approved by the Medical Ethics Committee of Peking University First Hospital (Beijing, China). Informed consent was acquired from the subjects after understanding the process and possible consequences of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"1"}}